ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2025

Modification of Structural Lesions on Magnetic Resonance Imaging By Etanercept: A 12-Week Randomized Placebo-Controlled Trial

Walter Maksymowych1, Stephanie Wichuk2, Maxime Dougados3, Heather Jones4, Annette Szumski5, Lisa Marshall4, Jack F Bukowski6 and Robert G Lambert7, 1Department of Medicine, University of Alberta, Edmonton, AB, Canada, 2Rheumatology Research Lab, University of Alberta, Edmonton, AB, Canada, 3Rheumatology Department, Hôpital Cochin, Paris, France, 4Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, 5Department of Biostatistics, Pfizer, Collegeville, PA, 6Clinical Affairs, Pfizer, Collegeville, PA, 7Department of Radiology & Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: axial spondyloarthritis, etanercept and inflammation, Lesions, MRI

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 9, 2015

Session Title: Imaging of Rheumatic Diseases II: MRI, PET and CT

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Modification
of structural lesions by anti-TNF therapy has not been demonstrated in a
randomized placebo (PBO)-controlled trial. The Spondyloarthritis
Research Consortium of Canada (SPARCC) sacroiliac joint (SIJ)
score
(SSS) assesses the degree of fat metaplasia (new tissue growth after resolution
of inflammation), erosion, backfill (new tissue growth at erosion site), and
ankylosis observed on MRI in the SIJ. This analysis evaluated the impact on
these lesions at 12 wks in patients with non-radiographic axial SpA receiving PBO
or etanercept (ETN) in the EMBARK study (ClinicalTrials.gov: NCT01258738).

Methods: Patients
had axial SpA per Assessment of SpondyloArthritis international Society (ASAS) criteria
without meeting modified NY radiographic criteria; BASDAI score ≥4; symptoms
for >3 months and <5 yrs; and had failed ≥2 NSAIDs. Patients were
randomized to double-blind ETN 50 mg/wk or PBO for 12 wks, then received
open-label ETN. Structural lesions were scored using the SPARCC SSS method on
T1-weighted spin echo (T1WSE) MRI. Two readers independently scored baseline
(BL) and 12-wk T1WSE MRI scans, blinded to patients, time point, and inflammation
scores assessed by short tau inversion recovery MRI scans. Readers’ mean
scores were used.

Results: Mean
(SD) age was 32 (7.8) yrs, 60.5% were male, duration of disease symptoms was 2.4
(1.8) yrs, 71.6% were human leukocyte antigen B27+, and 80.9% had sacroiliitis
on MRI (modified intent-to-treat [mITT] population, N=215). MRI
scans from 185 patients (ETN, n=88; PBO, n=97) with BL and 12-wk scans were
reviewed. At BL, there were no significant differences in mean SPARCC SSS
scores between ETN and PBO (table). From BL to 12 wks, change
in mean SPARCC SSS score was significantly greater for ETN than PBO for erosion
(-0.57
vs -0.08, respectively, p=0.009) and backfill (0.36
vs 0.06, p=0.021). This treatment difference is also presented in cumulative
probability plots (figure).

Conclusion: Treatment
with ETN was associated with significantly greater reduction in erosion and
increase in backfill at 12 wks vs. PBO, consistent with a very early reparative
response to anti-TNF therapy. The impact of this new data on disease
progression in SpA should be studied further.

Table. SPARCC SSS scores at baseline, week 12, and change from baseline to week 12

 

 

ETN

N=88

PBO

N=97

P-value*

ETN vs PBO

Δ BL to week 12

Erosion

Baseline

2.25 (0.33)

1.73 (0.32)

0.009

Week 12

1.68 (0.25)

1.65 (0.30)

Δ BL to week 12

-0.57 (0.16)

-0.08 (0.10)

Backfill

Baseline

0.76 (0.22)

0.64 (0.20)

0.021

Week 12

1.13 (0.29)

0.70 (0.23)

Δ BL to week 12

0.36 (0.12)

0.06 (0.06)

Fat Metaplasia

Baseline

0.50 (0.19)

0.27 (0.09)

ns

Week 12

0.56 (0.22)

0.32 (0.10)

Δ BL to week 12

0.06 (0.07)

0.05 (0.05)

Ankylosis

Baseline

0.15 (0.10)

0.13 (0.11)

ns

Week 12

0.15 (0.11)

0.13 (0.11)

Δ BL to week 12

0.01 (0.01)

0.01 (0.01)

Values are mean (standard error). Observed case analysis, mITT population.

*2-sample t-test.

BL SPARCC SSS scores did not differ significantly between ETN and PBO.

Treatment differences in Δ BL to week 12 for erosion and backfill remained significant after adjusting for BL SPARCC SSS scores using analysis of covariance models.

Δ, change; ns, non-significant.

Figure.
Cumulative probability of change from baseline to week 12 in the etanercept and
placebo groups for (A) erosion and (B) backfill.

A.

B.


Disclosure: W. Maksymowych, Abbvie, 5,Amgen, 5,Eli Lilly and Company, 5,Janssen Pharmaceutica Product, L.P., 5,Pfizer Inc, 5,UCB, 5,Abbvie, 2,Boehringer Ingelheim, 5; S. Wichuk, None; M. Dougados, Pfizer Inc, 5,UCB, 5,AbbVie, 5,Merck Pharmaceuticals, 5; H. Jones, Pfizer, Inc, 3,Pfizer, Inc, 1; A. Szumski, InVentiv Health, 3; L. Marshall, Pfizer Inc, 1,Pfizer Inc, 3; J. F. Bukowski, Pfizer Inc, 3; R. G. Lambert, None.

To cite this abstract in AMA style:

Maksymowych W, Wichuk S, Dougados M, Jones H, Szumski A, Marshall L, Bukowski JF, Lambert RG. Modification of Structural Lesions on Magnetic Resonance Imaging By Etanercept: A 12-Week Randomized Placebo-Controlled Trial [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/modification-of-structural-lesions-on-magnetic-resonance-imaging-by-etanercept-a-12-week-randomized-placebo-controlled-trial/. Accessed April 13, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/modification-of-structural-lesions-on-magnetic-resonance-imaging-by-etanercept-a-12-week-randomized-placebo-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.